MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

NewsGuard 100/100 Score
Apr 7 2010

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.  The data will be presented at the Annual Meeting of the American Academy of Neurology (AAN) in Toronto, Ontario on Wednesday, April 14, 2010.

Source:

MAP Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News | Women's Health News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
Lancet Commission predicts sharp increase in global prostate cancer cases
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
LabVantage celebrates customer success with record number of software deployments in FY 2024
Supply chain assessment and management, optimizing pharmaceutical supply chains

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry